One of the hottest biopharma and life sciences funds in recent years is confident that it can rebound from last year’s setback.
Stephen TaubFebruary 23, 2022
Andrey Rudakov/Bloomberg
The sharp selloff in fledgling biopharma and life sciences stocks in the past year or so has not spared RTW Investments. The fund was down more than 9 percent in 2021 and lost another 17.6 percent in January of this year.Even so, its recent setbacks
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.